---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-303934"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T04:43:46.321123+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm reports Phase 1 selinexor+ruxolitinib data: 92% spleen response at week 24 in myelofibrosis

## Summary
- At week 24, 92% (11/12) evaluable patients achieved ≥35% spleen volume reduction (SVR35).
- Median spleen volume reduction of 45% at week 12 and 49% at week 24.
- 67% (4/6) evaluable patients achieved ≥50% symptom reduction (TSS50) at week 24.
- 57% (13/23) transfusion-independent patients maintained or improved hemoglobin levels.
- Common grade 3-4 AEs: anemia (37%) and thrombocytopenia (21%), both reversible.

## SEC filing metadata
- accession: 0001193125-22-303934
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312522303934/0001193125-22-303934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312522303934/d426577d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-303934
- JSON: https://secwatch.observer/filing/0001193125-22-303934.json
- Plain text: https://secwatch.observer/filing/0001193125-22-303934.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.